The genes in our signature were related to tumor predisposition (NYNRIN [27], GPRC5C [24], and CLCN5 [28]), tumorigenesis (JAM3 [29], PGRMC1 [30], and LSP1 [31]), progression (DOCK1 [32], MAML1 [33], PGRMC1, NRIP1, and PDE4D [34]), migration and invasion (ADRM1 [35] and SPINT2 [36]), and chemotherapy sensitivities (ALDH2 [25], ETFB [37], ETS2 [38], CALCRL [23], SESN1 [39], and IL2RA [40]). This evidence concerns the gene MAML1 and neoplasm.